中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

57 records (took 0.028 seconds)

    FLAVONOLIGNANS FOR TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES
    22.
    发明申请
    FLAVONOLIGNANS FOR TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES 审中-公开

    公开(公告)号：US20180289666A1

    公开(公告)日：2018-10-11

    申请号：US15481720

    申请日：2017-04-07

    Applicant: Macau University of Science and Technology

    Inventor： Ying Xie ,  Liang Liu ,  Hua Zhou ,  Zhong-Wen Yuan ,  Yan-Fang Zheng ,  Sen-Ling Feng ,  Xiao-Hui Zeng ,  Hui Wang

    IPC: A61K31/366

    Abstract: A method for reducing abnormalities in lipid metabolism and for reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism includes administering an effective amount of a flavonolignan to the subject. The subject may additionally suffer from a liver disease, obesity, hypertension, diabetes mellitus or a metabolic syndrome. Further provided is a method for reducing the risk of a cardiovascular disease in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism and a method for reducing hepatic abnormalities and reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by hepatic abnormalities. Still further provided is a method for reducing liver damages associated with the treatment of rheumatoid arthritis with a disease-modifying antirheumatic drug or a non-steroidal anti-inflammatory drug.

    Neferine and the use thereof in treating huntington disease
    28.
    发明授权
    Neferine and the use thereof in treating huntington disease 有权
    奈非炔及其在治疗亨廷顿疾病中的应用

    公开(公告)号：US09119847B2

    公开(公告)日：2015-09-01

    申请号：US14562780

    申请日：2014-12-08

    Applicant: Macau University of Science and Technology

    Inventor： Yuen Kwan Law ,  Kam Wai Wong ,  Liang Liu

    IPC: A61K31/4725 ,  A61K36/185

    CPC classification number: A61K31/4725 ,  A61K36/62

    Abstract: The present invention discloses a method of treating neurodegenerative disorder comprising administering an effective amount of an alkaloid which is a bisbenzylisoquinline alkaloid isolated from the traditional Chinese medicinal herb Nelumbo nucifera. The pharmaceutical composition thereof for treating Huntington's disease is also disclosed.

    Abstract translation: 本发明公开了一种治疗神经变性疾病的方法，包括给予有效量的生物碱，所述生物碱是从中草药Nelumbo Nucumera分离的双苄基异喹啉生物碱。 还公开了其用于治疗亨廷顿病的药物组合物。

    Method of identifying a gene associated with a disease or pathological condition of the disease
    30.
    发明授权
    Method of identifying a gene associated with a disease or pathological condition of the disease 有权

    公开(公告)号：US10787708B2

    公开(公告)日：2020-09-29

    申请号：US15647414

    申请日：2017-07-12

    Applicant: Macau University of Science and Technology

    Inventor： Liang Liu ,  Lai Han Leung ,  Ying Li ,  Xiao Jun Yao ,  Hu Dan Pan

    IPC: C12Q1/6883 ,  G16B30/00 ,  G16B50/00 ,  G16B20/20 ,  G16B5/00 ,  G16B15/00 ,  G16B40/20 ,  C12Q1/6869

    Abstract: A method of identifying a gene associated with a disease or pathological condition of the disease includes: a) obtaining a first group of exome sequences from a first population suffering from the disease or pathological condition and a second group of exome sequences from a second population not having the disease or pathological condition; b) identifying one or more variants in the first group by comparing it with the second group, and optionally with a public database, to generate a first set of variant data; c) applying a variant quality score calibration tool with a truth sensitivity threshold to remove false-positive variants having a sensitivity lower than the threshold and background variants from the first set of variant data so as to obtain a second set of variant data; d) removing synonymous variants from the second set of variant data to obtain a third set of variant data; and e) identifying one or more deleterious variants from the third set of variant data using a gene burden analysis, optionally generating a fourth set of variant data.

Patent Agency Ranking